# A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Source: https://onco.cc/trials/nct07029399/  
OnCo record `nct07029399` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of NKT5097 run by NiKang Therapeutics, Inc., now recruiting.

## Summary

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors is a phase 1 interventional study registered as NCT07029399 by NiKang Therapeutics, Inc., with 361 participants planned, started 2025-03-25, primary completion expected 2027-07-31. Conditions recorded: HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer. Interventions recorded: NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07029399
- Phase: 1
- Setting: A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/CDK4 Dual Degrader NKT5097 in Adults With Advanced/Metastatic Solid Tumors
- Sponsor: NiKang Therapeutics, Inc.
- Enrolled: 361

## Sources

- ClinicalTrials.gov NCT07029399: https://clinicaltrials.gov/study/NCT07029399

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [NKT5097](https://onco.cc/drugs/nkt5097/)
- companies: [NiKang Therapeutics](https://onco.cc/companies/nikang-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07029399.json